In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Marinus Pharmaceuticals, Inc.. Trade Record

NASDAQ:MRNS Marinus Pharmaceuticals, Inc. stock gains 170.45% Exit Oct 9, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart MRNS Aug 9, 2017, priceSeries
About Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. The company is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat adults with refractory focal onset epileptic seizures; and is in Phase II clinical trials for the treatment of genetic orphan disorders, as well as is in Phase II clinical trial to treat Fragile X Syndrome, an orphan indication. The company is also developing ganaxolone IV formulation to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreement with Purdue Neuroscience Company. The company was founded in 2003 and is based in Radnor, Pennsylvania.

Trade Information
Trade Type
Entry Date
Aug 9, 2017
Entry Price
Sell Date
Oct 9, 2017
Sell Price
Net Gain
Hold Time
42 Trading Days